Session » Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

Date: Monday, November 8, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1328

Assessment of Microvascular Involvement in Psoriatic Arthritis by Nailfold Capillaroscopy

8:30AM-10:30AM: Abstract Number: 1322

Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy

8:30AM-10:30AM: Abstract Number: 1319

Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients

8:30AM-10:30AM: Abstract Number: 1306

Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients

8:30AM-10:30AM: Abstract Number: 1310

Clinical Characteristics of Patients with SpA and Concomitant IBD: Results from the ASAS PerSpA Study

8:30AM-10:30AM: Abstract Number: 1311

De Novo Psoriasis Can Be Reported at Any Timepoint in Early Axial Spondyloarthritis: An Analysis of 6 Years of Follow-up of the DESIR Cohort

8:30AM-10:30AM: Abstract Number: 1326

Epidemiology of Comorbidities in an Incident Psoriasis Cohort: A Population-Based Study

8:30AM-10:30AM: Abstract Number: 1308

Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and Rheumatoid Arthritis Patients Compared to Controls

8:30AM-10:30AM: Abstract Number: 1327

Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitors, IL17 Inhibitors and Oral Small Molecules

8:30AM-10:30AM: Abstract Number: 1309

Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS

8:30AM-10:30AM: Abstract Number: 1317

Impairment of Memory in Axial Spondyloarthritis?

8:30AM-10:30AM: Abstract Number: 1304

Increased Risk of Vertebral Fracture Among Patients with Psoriatic Arthritis: A Systematic Review and Meta-analysis

8:30AM-10:30AM: Abstract Number: 1318

Interplay Between Covid-19 and Spondyloarthritis or Its Treatment

8:30AM-10:30AM: Abstract Number: 1320

Obesity and Its Associations with Clinical Manifestations and Disease Burden of Patients with Spondyloarthritis: An Ancillary Study from the ASAS-perSpA Project

8:30AM-10:30AM: Abstract Number: 1325

Osteoporosis in Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1314

Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis

8:30AM-10:30AM: Abstract Number: 1315

The Best Cardiovascular Risk Algorithm to Predict the Presence of Carotid Plaque in Psoriatic Arthritis Patients

8:30AM-10:30AM: Abstract Number: 1313

The Impact of Comorbidities on Patients with Axial Spondyloarthritis: A Cluster Analysis

8:30AM-10:30AM: Abstract Number: 1305

Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study

8:30AM-10:30AM: Abstract Number: 1324

Uveitis in 301 Patients with Axial Spondyloarthritis of a Single University Center: Epidemiology, Clinical Features and Biological Treatment

8:30AM-10:30AM: Abstract Number: 1323

Uveitis in 406 Patients with Psoriatic Arthritis: Epidemiology, Clinical Characteristics and Relationship with Biological Treatment. Study of a Single University Center

8:30AM-10:30AM: Abstract Number: 1321

Uveitis in Patients with Psoriatic Arthritis – a Database Analysis

8:30AM-10:30AM: Abstract Number: 1307

Uveitis in Spondyloarthritis Patients. Is There Any Specific Clinical Picture?

8:30AM-10:30AM: Abstract Number: 1316

Vitamin D Deficiency and Disease Activity in Patients with Spondyloarthritis

8:30AM-10:30AM: Abstract Number: 1312

What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].